The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy

Kornetova E.G.; Galkin S.A.; Mednova I.A.; Tsiguntsev V.V.; Paderina D.Z.; Ivanova S.A.

doi:https://doi.org/10.17116/jnevro202512501198

Kornetova E.G.

Mental Health Research Institute — Tomsk National Research Medical Center, Russian Academy of Science

ORCID: 0000-0002-5179-9727

Galkin S.A.

Mental Health Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Science

ORCID: 0000-0002-7709-3917

Mednova I.A.

Mental Health Research Institute — Tomsk National Research Medical Center, Russian Academy of Science

ORCID: 0000-0002-8057-3305

Tsiguntsev V.V.

Mental Health Research Institute — Tomsk National Research Medical Center, Russian Academy of Science

ORCID: 0000-0001-9083-0339

Paderina D.Z.

Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Science

ORCID: 0000-0002-5546-7316

Ivanova S.A.

Mental Health Research Institute — Tomsk National Research Medical Center, Russian Academy of Science

ORCID: 0000-0001-7078-323X

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy

Authors:

Kornetova E.G., Galkin S.A., Mednova I.A., Tsiguntsev V.V., Paderina D.Z., Ivanova S.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(1): 98‑104

DOI: 10.17116/jnevro202512501198

Read: 1123 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kornetova EG, Galkin SA, Mednova IA, Tsiguntsev VV, Paderina DZ, Ivanova SA. The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(1):98‑104. (In Russ.)
https://doi.org/10.17116/jnevro202512501198

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the associations of NOS1AP gene polymorphisms with the duration of the QT interval (QTc) in patients with schizophrenia receiving antipsychotics.

MATERIAL AND METHODS

One hundred and sixty-eight patients (78 men and 90 women) with an established diagnosis of schizophrenia were examined. The patients received basic antipsychotic therapy. At the time of admission to the hospital, a standard 12-lead electrocardiogram recording was performed. The calculation of the QTc interval was carried out using the Bazett formula. Three NOS1AP polymorphisms (rs12029454, rs10494366 and rs12143842) were selected for genotyping.

RESULTS

Spearman’s correlation revealed a significant relationship between CPZeq and the duration of the QTc interval in the group of men (r_s=0.262; p=0.021; p_Bonf=0.042). CPZeq was positively correlated with the duration of the QTc interval in men with AA and AG rs12029454 (r_s=0.717; p=0.00025; p_bonf=0.0015), GG and GT rs10494366 (r_s=0.381; p=0.008; p_bonf=0.048), TT and CT rs12143842 (r_s=0.389; p=0.003; p_bonf=0.018) genotypes. We did not find any significant correlations in the group of women.

CONCLUSION

Genetic variants rs12029454, rs10494366 and rs12143842 of the NOS1AP gene are associated with the duration of the QTc interval in men with schizophrenia in response to antipsychotics. The AA/AG rs12029454, GG/GT rs10494366 and TT/CT rs12143842 genotypes in men contribute to the prolongation of the QTc interval and the development of undesirable cardiovascular disorders against the background of antipsychotic therapy.

Keywords:

schizophrenia

gene polymorphisms

NOS1AP

QT interval

antipsychotics

therapy

Authors:

Kornetova E.G.

Mental Health Research Institute — Tomsk National Research Medical Center, Russian Academy of Science

ORCID: 0000-0002-5179-9727

Galkin S.A.

Mental Health Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Science

ORCID: 0000-0002-7709-3917

Mednova I.A.

Mental Health Research Institute — Tomsk National Research Medical Center, Russian Academy of Science

ORCID: 0000-0002-8057-3305

Tsiguntsev V.V.

Mental Health Research Institute — Tomsk National Research Medical Center, Russian Academy of Science

ORCID: 0000-0001-9083-0339

Paderina D.Z.

Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Science

ORCID: 0000-0002-5546-7316

Ivanova S.A.

Mental Health Research Institute — Tomsk National Research Medical Center, Russian Academy of Science

ORCID: 0000-0001-7078-323X

Received:

06.09.2024

Accepted:

26.09.2024

Close metadata

References:

Tkachev AI, Stekolshchikova EA, Morozova AYu, et al. Ceramides: shared lipid biomarkers of cardiovascular disease and schizophrenia. Consortium Psychiatricum. 2021;2(3):35-43. https://doi.org/10.17816/CP101
Rukavishnikov GV, Kasyanov ED, Zhilyaeva TV, et al. Schizophrenia and cardiometabolic disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6):132-138. (In Russ.). https://doi.org/10.17116/jnevro2021121061132
Fan Z, Wu Y, Shen J, et al. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013;47(11):1549-1556. https://doi.org/10.1016/j.jpsychires.2013.07.011
Malin DI, Bulatova DR, Shustova LY. QT interval prolongation syndrome in patients with schizophrenia at the city psychiatric hospital. Social’naya i klinicheskaya psihiatriya. 2024;34(1):19-25. (In Russ.).
Galkin SA, Kornetova EG, Mednova IA, et al. Prevalence and risk factors of QT prolongation syndrome in patients with schizophrenia while taking antipsychotics. Sovremennaya terapiya psihicheskih rasstrojstv. 2024;(2):32-39. (In Russ.).
Mazo GE, Kibitov AO. Risk management of metabolic disorders in the use of antipsychotics. Obozrenie psihiatrii i medicinskoj psihologii imeni V.M. Bekhtereva. 2016;(3):85-97. (In Russ.).
Trinkley KE, Page RL, Lien H, et al. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719-1726. https://doi.org/10.1185/03007995.2013.840568
Yavelov IS. Sudden cardiac death in metabolic syndrome. Trudnyj pacient. 2012;10(6):34-39. (In Russ.).
Park B, Lee YJ. Metabolic syndrome and its components as risk factors for prolonged corrected QT interval in apparently healthy Korean men and women. Journal of clinical lipidology. 2018;12(5):1298-1304. https://doi.org/10.1016/j.jacl.2018.07.004
Cappelli S, Spalloni A, Feiguin F, et al. NOS1AP is a novel molecular target and critical factor in TDP-43 pathology. Brain Commun. 2022;4(5):fcac242. https://doi.org/10.1093/braincomms/fcac242
Brzustowicz LM. NOS1AP in schizophrenia. Curr Psychiatry Rep. 2008;10(2):158-163. https://doi.org/10.1007/s11920-008-0027-0
Mednova IA, Pozhidaev IV, Tiguntsev VV, et al. NOS1AP Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with Schizophrenia. Biomedicines. 2024;12(3):627. https://doi.org/10.3390/biomedicines12030627
Soroush N, Aarnoudse AJ, Kavousi M, et al. A NOS1AP gene variant is associated with a paradoxical increase of the QT-interval shortening effect of digoxin. Pharmacogenomics J. 2022;22(1):55-61. https://doi.org/10.1038/s41397-021-00256-2
Arking DE, Pfeufer A, Post W, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet. 2006;38(6):644-651. https://doi.org/10.1038/ng1790
Aarnoudse AJ, Newton-Cheh C, de Bakker PI, et al. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation. 2007;116(1):10-16. https://doi.org/10.1161/CIRCULATIONAHA.106.676783
Eijgelsheim M, Aarnoudse AL, Rivadeneira F, et al. Identification of a common variant at the NOS1AP locus strongly associated to QT-interval duration. Hum Mol Genet. 2009;18(2):347-357. https://doi.org/10.1093/hmg/ddn341
Earle N, Ingles J, Bagnall RD, et al. NOS1AP Polymorphisms Modify QTc Interval Duration But Not Cardiac Arrest Risk in Hypertrophic Cardiomyopathy. J Cardiovasc Electrophysiol. 2015;26(12):1346-1351. https://doi.org/10.1111/jce.12827
Esen-Sehir D, Kopf J, Hägele S, et al. Influence of NOS1AP Risk Variants on the Corrected QT (QTc) Interval in the Pharmacotherapy of Schizophrenia. Pharmacopsychiatry. 2022;55(5):266-273. https://doi.org/10.1055/a-1811-7241
Nesterets AM, Kuznetsov AA, Ivanova AA, et al. Association of single nucleotide polymorphic variants of the NOS1AP gene with QT interval duration. Kompleksnye problemy serdechno-sosudistyh zabolevanij. 2022;11(2):18-26. (In Russ.). https://doi.org/10.17802/2306-1278-2022-11-2-18-26
Kay SR, Opler LA, Fiszbein A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
Mosolov SN. Scales of psychometric assessment of schizophrenia symptoms and the concept of positive and negative disorders. M. 2001;238. (In Russ.).
Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-370.
Surawicz B, Childers R, Deal BJ, et al. American Heart Association Electrocardiography and Arrhythmias Committee. J Am Coll Cardiol. 2009;53(11):976-981. https://doi.org/10.1016/j.jacc.2008.12.013
Smith A, Auer D, Johnson M, et al. Cardiac muscle-restricted partial loss of NOS1AP expression has limited but significant impact on electrocardiographic features. G3 (Bethesda). 2023;13(11):jkad208. https://doi.org/10.1093/g3journal/jkad208
Arking DE, Pulit SL, Crotti L, et al. Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nat Genet. 2014;46(8):826-836. https://doi.org/10.1038/ng.3014
Mitchell RN, Ashar FN, Jarvelin MR, et al. Effect of Sex and Underlying Disease on the Genetic Association of QT Interval and Sudden Cardiac Death. J Am Heart Assoc. 2019;8(23):e013751. https://doi.org/10.1161/JAHA.119.013751
Crotti L, Monti MC, Insolia R, et al. NOS1AP is a genetic modifier of the long-QT syndrome. Circulation. 2009;120(17):1657-1663. https://doi.org/10.1161/CIRCULATIONAHA.109.879643
Malin DI, Ryvkin PV, Bulatova DR. Long QT syndrome in the use of antipsychotic and antidepressant drugs. Sovremennaya terapiya psihicheskih rasstrojstv. 2023;(2):48-56. (In Russ.). https://doi.org/10.21265/PSYPH.2023.69.57.006
Nasyrova RF, Kidyaeva AV, Grechkina VV, et al. A personalized approach to the prediction and prevention of haloperidol-induced prolongation of the QT interval: a short review. Farmakogenetika i farmakogenomika. 2024;(1):20-30. (In Russ.). https://doi.org/10.37489/2588-0527-2024-1-20-30